Preferential Dependence of Breast Cancer Cells versus Normal Cells on Integrin-Linked Kinase for Protein Kinase B/Akt Activation and Cell Survival
Open Access
- 1 January 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 66 (1) , 393-403
- https://doi.org/10.1158/0008-5472.can-05-2304
Abstract
The emerging paradigm of “oncogene addiction” has been called an Achilles' heel of cancer that can be exploited therapeutically. Here, we show that integrin-linked kinase (ILK), which is either activated or overexpressed in many types of cancers, is a critical regulator of breast cancer cell survival through the protein kinase B (PKB)/Akt pathway but is largely dispensable for the survival of normal breast epithelial cells and mesenchymal cells. We show that inhibition of ILK activity with a pharmacologic ILK inhibitor, QLT-0267, results in the inhibition of PKB/Akt Ser473 phosphorylation, stimulation of apoptosis, and a decrease in mammalian target of rapamycin (mTOR) expression in human breast cancer cells. In contrast, QLT-0267 treatment has no effect on PKB/Akt Ser473 phosphorylation or apoptosis in normal human breast epithelial, mouse fibroblast, or vascular smooth muscle cells. The inhibition of PKB/Akt Ser473 phosphorylation by QLT-0267 in breast cancer cells was rescued by a kinase-active ILK mutant but not by a kinase-dead ILK mutant. Furthermore, a dominant-negative ILK mutant increased apoptosis in the MDA-MB-231 breast cancer cell line but not in normal human breast epithelial cells. The inhibitor was active against ILK isolated from all cell types but did not have any effect on cell attachment and spreading. Our data point to an “ILK addiction” of breast cancer cells whereby they become dependent on ILK for cell survival through the mTOR-PKB/Akt signaling pathway and show that ILK is a promising target for the treatment of breast cancer. (Cancer Res 2006; 66(1): 393-403)Keywords
This publication has 51 references indexed in Scilit:
- Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancerMolecular Cancer Therapeutics, 2005
- RNA Interference Demonstrates a Novel Role for Integrin-Linked Kinase as a Determinant of Pancreatic Adenocarcinoma Cell Gemcitabine ChemoresistanceClinical Cancer Research, 2005
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR ComplexScience, 2005
- Integrin-linked kinase: a cancer therapeutic target unique among its ILKNature Reviews Cancer, 2005
- RGD peptides confer survival to hepatocytes via the β1-integrin-ILK-pAkt pathwayJournal of Hepatology, 2004
- Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitiveNature Cell Biology, 2004
- αv integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cellsOncogene, 2003
- Inhibition of protein kinase B/AktPharmacology & Therapeutics, 2002
- Inhibition of integrin linked kinase (ILK) suppresses β-catenin-Lef/Tcf-dependent transcription and expression of the E-cadherin repressor, snail, in APC−/− human colon carcinoma cellsOncogene, 2001
- Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolinesBreast Cancer Research and Treatment, 1996